This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The 5 Dumbest Things on Wall Street This Week: June 28

McKesson's Moolah

Thank you, Wall Street Journal, for your detailed reporting on McKesson (MCK) CEO John Hammergren's record-setting pension. Try as we might, there was no way we here at the Dumbest Lab could have made those calculations.

We simply can't count that high.

Hammergren, who started at the drug distributor back in 1996 and became co-CEO in 1999, would have pocketed $159 million had he voluntarily retired from the company on March 31, according to the WSJ. The Journal's compensation consultants proclaimed it the largest pension kitty on file for current CEOs, and undoubtedly the biggest retirement plan in corporate history.

Take that, Dick Grasso! You thought your $126 million parting gift from the NYSE was hairy, but Hammergren's deal totally hammers your pissant package.

To be fair, Grasso was a quasi-civil servant who was forced to scratch by on his salary during lean years like 2001 when he pulled in $25.6 million, so he needed the big nest egg.

Not so for Hammergren, who ranks atop Forbes CEO salary list with a six-year average compensation of $50.79 million. Over the past five years, he's been paid $285 million dollars, which makes us think that his pension plan may be a wee bit over the top.

Of course, McKesson investors may argue that their own 401(k) accounts have been sufficiently plumped by the stock's growth during Hammergren's reign. McKesson's stock price has more than tripled in his 14 years atop the company, outperforming the S&P 500 along the way.

That said, the vast majority of that outperformance vs. the index has been since 2006, when the Medicare Prescription Drug, Improvement, and Modernization Act officially kicked in. Familiarly known as the prescription drug act, it expanded coverage nationwide and introduced an entitlement benefit for well-known drugs through tax breaks and subsidies.

It also seems to have given McKesson a sense of entitlement as well. The drug wholesaler paid the federal government $190 million in 2012, and tens of millions more to the states on top of that, to settle lawsuits that it illegally inflated drug prices.

If you look at it that way, Hammergren owes a lot of his success -- and retirement riches -- not just to McKesson's boorish board and cockeyed compensation consultants, but to George W. Bush for signing that act into law. Maybe he should buy one of W's paintings or donate some of his pension pile to his presidential library to show his appreciation.

As for McKesson shareholders, though, maybe they should ask for some of their money back. Or at least press the board for answers as to why Hammergren is seeing all that green that should be going to them.

3 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,067.56 -30.89 -0.18%
S&P 500 2,002.28 -1.09 -0.05%
NASDAQ 4,598.1880 +17.9170 0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs